Natera Announces Surveillance Analysis From Phase 3 IMvigor011 Trial in Muscle-Invasive Bladder Cancer, Data Shows Patients Who Remain Signatera MRD-negative After Surgery May Be Spared From Adjuvant Treatment, With 100% Overall Survival At 12 Months
Benzinga Newsdesk - Apr 5, 2024, 7:04AM